# Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

> **NCT04894110** · PHASE1 · COMPLETED · sponsor: **Emmecell** · enrollment: 42 (actual)

## Conditions studied

- Corneal Edema
- Corneal Endothelial Dysfunction
- Corneal Endothelial Dystrophy
- Fuchs Dystrophy
- Fuchs Endothelial Corneal Dystrophy
- Pseudophakic Bullous Keratopathy
- Bullous Keratopathy
- Endothelial Dysfunction
- Moderate Corneal Endothelial Decompensation

## Interventions

- **BIOLOGICAL:** EO2002
- **BIOLOGICAL:** EO2002 low dose
- **BIOLOGICAL:** EO2002 mid dose
- **BIOLOGICAL:** EO2002 high dose

## Key facts

- **NCT ID:** NCT04894110
- **Lead sponsor:** Emmecell
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-22
- **Primary completion:** 2024-10-03
- **Final completion:** 2024-10-03
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04894110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04894110, "Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT04894110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*